Actinium Pharmaceuticals received acceptance of its compliance plan from NYSE Regulation, granting a maximum extension period through November 27, 2027, to regain compliance with listing standards regarding minimum bid price and shareholder equity. The company's common stock will continue trading on NYSE American under the symbol ATNM during this period, subject to periodic reviews of its progress. Concurrently, Actinium announced intellectual property advances for its Actimab-A program, including newly issued US patents for solid tumor treatments and pre-grant status for AML combination therapies. The company also expanded manufacturing capacity by adding a second supplier for Actimab-A to support upcoming clinical milestones in the second half of 2026 and throughout 2027. Actinium Pharmaceuticals is a biopharmaceutical company developing targeted radiotherapies for cancer treatment.

Actinium Pharmaceuticals, Inc. submitted a compliance plan to NYSE American on June 18, 2026, to address non-compliance with stockholders' equity requirements. The company was notified on May 27, 2026, that it failed to maintain the minimum $4.0 million stockholders' equity threshold required by the exchange. Actinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing radiopharmaceuticals for cancer treatment.